Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease

International Journal of Clinical Practice

Volumn 55, Issue 3, 2001, Pages 171-176

  Olsson, A M ^a   Persson, C A ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Sildenafil Investigators Group   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; NITRATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; POPULATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035027524     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. NIH Consensus Development Panel on Impotence. Impotence. NIH Consensus Conference. JAMA 1993; 270: 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Greenstein A, Chen J, Miller H el al. Does severity of ischemie coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-126.
4. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181-184.
5. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 22: 699-709.
6. Papadopoulos C, Shelley SI, Piccolo M et al. Sexual activity after coronary bypass surgery. Chest 1986; 90: 681-685.
7. Rosen RC, Riley A, Wagner G el al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
8. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
9. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemie heart disease. Am J Cardiol 1999; 83(suppl SA): 29C-34C.
10. Hermann HC, Chang G, Klugherz B, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626.
11. Katz SD, Balidemaj K, Homma S et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances endothelium-dependent, flow-mediated vasodilation in patients with chronic heart failure [abstract]. Circulation 1999; 100: 1861.
12. Kloner RA, Brown M, Prisant LM, Collins M. Efficacy and safety of Viagra (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy. Am J Hypertens. In press.
13. Lepore JL, Pereira N, Maroo A el al. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilation by inhaled nitric oxide in patients with pulmonary hypertension [abstract]. Circulation 1999; 100:1240.
14. Prisant LM, Brown M. Sildenafil citrate: well-tolerated by patients with erectile function taking concomitant antihypertensive therapy [abstract]. Am J Hypertens 1999; 12: 10A-11A.
15. Rosano G, Leonardo F, Pelliccia F et al. Effect of sildenafil upon myocardial ischemia in patients with chronic stable angina in therapy with beta-bloekers [abstract]. J Urol 1999; 161(suppl 4): 211.
16. Vardi Y, Klein L, Masarwa O, Spreecher E. Effect of sildenafil on ambulatory blood pressure monitoring in hypertensive and non-hypertensive impotent males [abstract]. J Urol 1999; 161(suppl 4): 212.
17. Muller JE, Mittleman A, Maclure M et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA 1996; 275: 1405-1409.
18. Cheitlin MD, Mutter AM, Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Cardiology 1999; 99: 168-177.
19. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999; 84: 11N-17N.
20. Hutter AM. Recommendations for using sildenafil in men at risk of CV effects. Modern Med 1998; 66: 38.
21. DeBusk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol 2000; 86: 175-181.
22. Morales A, Gingell C, Collins M et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.